Pioneering molecular medicine research since 1998 — funded by the National Cancer Institute (NIH) under the RAPID program. From the discovery of Arishinin to international protein registration, AIMM drives drug discovery and genetic analysis at ACU.
The Adichunchanagiri Institute of Molecular Medicine (AIMM) has been functioning alongside the AIMS Central Research Laboratory since 1998. From its inception, AIMM's research program has been centered around dietary antioxidants in the prevention of oxidative stress — a recognized etiological factor for diseases including cancer, arthritis, cataract, heart ailments, snake bite, malaria, and bacterial/fungal infections.
The institute was funded by the National Cancer Institute of the National Institutes of Health (NIH-NCI) towards developing the Turmeric peptide as a possible cancer preventive biomolecule under the RAPID (Research And Prevention through Interdisciplinary Discovery) program — making AIMM one of a select few institutions worldwide to receive this prestigious research support.
AIMM holds a US Patent (US 8,389,677B2) for the discovery of Arishinin, a novel anti-inflammatory compound from Turmeric — the first international drug discovery from ACU.
Four groundbreaking discoveries that have advanced molecular medicine, established international patents, and registered proteins in global databases.
A novel anti-inflammatory compound from Turmeric with a molecular weight of 8 kDa. This very potent antioxidant was developed under the NIH-NCI RAPID program as a cancer preventive biomolecule. Patented at the Chennai patent office (Indian patent) and awarded a US patent.
AIMM identified and characterized Severe Combined Immunodeficiency (SCID) cases through molecular diagnostics, contributing to early diagnosis protocols for this rare genetic disorder. A breakthrough in immunodeficiency detection methodology.
Advanced understanding of immune system genetic disorders through molecular analysis at AIMM. PID-15 identification contributed to a deeper knowledge of primary immunodeficiency variants and their clinical significance.
A novel protein isolated from Turmeric, purified, sequenced, and registered in the international UniProt protein database — the first such registration by an Indian university. Among the top 2 entities in citation ranking among 2,000+ publications.
AIMM houses a comprehensive suite of advanced instruments for molecular biology, protein chemistry, cell culture, and drug discovery research.
Additional equipment: BOD Incubator, Autoclave, Fume Hoods, Laminar Air Flow Cabinet, Ice Flaker, Deep Freezer, Biosafety Cabinet Class II, Liquid Storage Containers, and more.
Currently, AIMM focuses on synthesis and development of new chemical entities and drug-like small molecules, targeting critical diseases through identification of lead molecules, screening hits, and optimization for affinity, selectivity, efficacy, metabolic stability, and bioavailability.
Developing anti-proliferative compounds and heterocyclic molecules targeting DNA repair proteins and cancer metastasis pathways.
Developing new chemical entities for the treatment of Leishmaniasis, a neglected tropical disease affecting millions worldwide.
Identifying small molecules and biomarkers for cardiovascular diseases and diabetes through advanced molecular analysis.
Molecular diagnostics for immunodeficiency disorders including SCID and primary immunodeficiency variant characterization.
Proteomics research including protein isolation, purification, sequencing, and international database registration.
Screening natural products and dietary compounds for therapeutic potential, continuing AIMM's legacy of turmeric-based discoveries.
AIMM is led by experienced principal investigators in molecular medicine, biochemistry and drug discovery, supported by Ph.D. scholars and research associates. Faculty profiles will be published shortly via the central FMS faculty directory.
Faculty profiles will be published soon.
Detailed AIMM faculty profiles, qualifications and research interests will be available here once integrated with the central Faculty Management System.
AIMM's advanced instruments (worth INR 2 Crore) are available to ACU faculty, Ph.D. scholars, approved external researchers, and industry partners through MoU agreements. Access is granted on a request-based model.
Access AIMM's advanced instruments — from Tecan automation, real-time PCR, ÄKTA Pure protein purification, flow cytometry, and ultra-low temperature storage.
Partner with AIMM faculty on joint research in cancer biology, immunology, drug discovery, natural product chemistry and protein characterization.
Pursue your Ph.D. at AIMM with access to cutting-edge molecular medicine instruments and mentorship from experienced researchers.
Reports, brochures and documentation related to AIMM's research, equipment and collaborative programs. Resource downloads will be added here once finalised.
Resource library will be published shortly.
Brochures, instrument catalogues, publication lists and collaboration MoUs will be available here.
Workshops, seminars, publications and announcements from AIMM. The events feed will be populated soon.
News & events will be updated regularly.
Check back for the latest workshops, seminars and research announcements from the Adichunchanagiri Institute of Molecular Medicine.
Interested in molecular medicine research, facility access, or collaborative opportunities? Reach out to AIMM and begin your journey in drug discovery and molecular diagnostics.